Advanced search
Start date
Betweenand

Assessment of the humoral immune response after the bivalent mRNA vaccine against SARS-Cov-2 through the PhIP-Seq technique

Grant number:23/13212-8
Support Opportunities:Regular Research Grants
Start date: February 01, 2024
End date: July 31, 2026
Field of knowledge:Biological Sciences - Immunology - Immunochemistry
Principal Investigator:Carlos Roberto Prudencio
Grantee:Carlos Roberto Prudencio
Host Institution:Instituto Adolfo Lutz (IAL). São Paulo , SP, Brazil
City of the host institution:São Paulo
Associated researchers:José Angelo Lauletta Lindoso ; Marisa Ailin Hong ; Siomar de Castro Soares
Associated scholarship(s):25/01152-6 - Development of platform for diagnosis Sars-cov-2 serology., BP.MS
25/20847-5 - Development of a platform for serological diagnosis of SARS-CoV-2, BP.TT
24/06776-5 - Assessment of the humoral immune response after bivalent mRNA vaccination against SARS-Cov-2 using the PhIP-Seq technique, BP.TT

Abstract

The widespread use of bacteriophages over the last hundred years is based on the structural diversity of these viral particles. Different types of bacteriophages participated in innovative studies that allowed the development of new biotechnological techniques. Among them, the phage display technique stands out, which allows the construction of antibodies or peptide libraries generated from a study target, such as the human peptidome. With this, it is possible to directly correlate genotype and phenotype and with the possibility of selecting molecules that bind with high affinity to their targets under different physicochemical conditions. The technique of high-throughput sequencing of a phage library expressing on its surface a set of different peptides that correspond to a particular target of study, such as the human virome, after incubation and immunoprecipitation with biological samples is called PhIP-Seq ( from Phage Immunoprecipitation Sequencing). Within the scope of immunovirology, it is possible to study the human virome, understand and monitor an individual's viral exposure throughout their life, as well as prospect new pharmacological targets and target molecules for diagnostic tests and vaccines. The Covid-19 pandemic has had an impact on the economy and on biopsychosocial aspects of the world's population. In 2023, some individuals still face sequelae due to Covid-19 and people continue to die due to SARS-Cov-2 infection. World health surveillance bodies continue to monitor variants of interest that may escape current vaccine coverage. Considering the possibility of epitope mapping offered by the PhIP-Seq technique, this project aims to study the immunological repertoire developed from the application of the bivalent mRNA vaccine to patients immunized at the Emílio Ribas Institute of Infectology (IIER). (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(The scientific publications listed on this page originate from the Web of Science or SciELO databases. Their authors have cited FAPESP grant or fellowship project numbers awarded to Principal Investigators or Fellowship Recipients, whether or not they are among the authors. This information is collected automatically and retrieved directly from those bibliometric databases.)
DA COSTA, HERNAN HERMES MONTEIRO; SILVA, VALERIA OLIVEIRA; AMORIM, GUSTAVO CARVALHO; GUERESCHI, MARCIA GRANDO; SERGIO, LUCIANA MARCIANO; GOMES, CARLOS HENRIQUE RODRIGUES; HONG, MARISA AILIN; DE OLIVEIRA, ELAINE LOPES; BRIGIDO, LUIS FERNANDO DE MACEDO; LINDOSO, JOSE ANGELO LAULETTA; et al. Assessment of an in-house IgG ELISA targeting SARS-CoV-2 RBD: Applications in infected and vaccinated individuals. JOURNAL OF IMMUNOLOGICAL METHODS, v. 530, p. 12-pg., . (23/13212-8, 21/11936-3, 23/06453-9, 22/05566-1)